Michael Gerard Email

General Counsel . Cabaletta Bio

Current Roles

Employees:
146
Revenue:
$11M
About
Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabalettaᅢᄁ¬ツᆲ¬トᄁs therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The platform is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop the CAAR T technology to treat B cell-mediated autoimmune diseases. The Companyᅢᄁ¬ツᆲ¬トᄁs lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris (mPV), which is a rare skin disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. The IND for the lead product candidate, DSG3-CAART, was accepted in September 2019 and was granted Fast Track Designation by the FDA in May 2020. The Phase 1 clinical trial for DSG3-CAART is now open for recruitment.
Cabaletta Bio Address
2929 Arch St
Philadelphia, PA
United States
Cabaletta Bio Email

Past Companies

Cabaletta BioGeneral Counsel
Spark Therapeutics, Inc.Associate General Counsel
SandozExecutive Director, Associate General Counsel - BD&L, Strategy and Portfolio

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.